Stock Ratings / Health Care / ISPC / earnings

BIAF (29) ONMD (26) MXCT (35) NRC (67) ⌘ Pro Terminal →

iSpecimen Inc. (ISPC) Next Earnings Date & Expected ±12.5% Move

Q: When is ISPC's next earnings date?

Based on SEC filing cadence, iSpecimen Inc. (ISPC)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is ISPC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ISPC, spanning a range between $1 and $0.93.

$0.83 +4.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

iSpecimen Inc. (ISPC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ISPC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ISPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, iSpecimen Inc. (NASDAQ: ISPC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.83 (+4.19% 1D, market cap $2.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ISPC ranks #868 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ISPC compare to BIAF and ONMD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ISPC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 11.2%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $26.3M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ISPC?

▼

Per ISPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001558569), iSpecimen Inc. generated $1.9M in revenue (-79.2% YoY), -$10.5M in net income, and -$4.2M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.83 (+0.56%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ISPC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY ISPC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 11.2% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.08-15.7% Next Q

Q2 (-2Q)

Grade E$0.91-7.7% Next Q

Q3 (-1Q)

Grade E$0.84-1.2% Next Q

Current

Grade E$0.83-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ISPC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ISPC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.21) and Max Pain ($0.87) forces dealer call-delta covering toward $34.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ISPC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ISPC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.10 Expected Swing

MODEL EARNINGS SETUP GAUGE

ISPC Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: -65%

Model Bullish Setup (30/100)Model Risk Weight (70/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$1.9M	-$10.5M	-$4.2M	11.2%
FY 2024	2024-12-31	$9.3M	-$12.5M	-$8.3M	45%
FY 2023	2023-12-31	$9.9M	-$11.1M	-$5.8M	11.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ISPC)

✓Walkthrough of ISPC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ISPC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.63%⚡ TESTING RESISTANCE

2026-11-02O $0.87H $0.87L $0.79C $0.83VOL 2.59M

RES: $0.95SUP: $0.75SMA50: $1.21SMA200: $4.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ISPC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ISPC Butterfly Map → + Track ISPC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ISPC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ISPC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ISPC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ISPC)

Health Care Rank #868 of 1016 ⚔️ BIAF vs ISPC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ISPC vs. BIAF, ONMD, MXCT, NRC)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, iSpecimen Inc. (ISPC) ranks #868 by composite RQD confidence (30/100, grade E) and #998 by equity capitalization ($2.0M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ISPC at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ISPC ACTIVE iSpecimen Inc.	E	30/100	—	11.2%	-35.0%	+4.19%	$2.0M	Benchmark Subject
BIAF bioAffinity Technologies Inc.	E	29/100	—	—	-35.0%	-3.96%	$3.9M	/biaf-vs-ispc →
ONMD OneMedNet Corp (Class A)	E	26/100	—	-30.0%	-35.0%	-3.43%	$26.3M	/onmd-vs-ispc →
MXCT MaxCyte Inc.	D-	35/100	—	96.0%	-27.1%	-8.09%	$178.5M	/mxct-vs-ispc →
NRC NRC Health	C+	67/100	44.8x	—	21.0%	+1.45%	$519.6M	/nrc-vs-ispc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001558569

In its most recent audited fiscal period (FY2025, filed 2025-12-31), iSpecimen Inc. (ISPC) reported GAAP revenue of $1.9M (-79.2% vs. FY2024 revenue of $9.3M , and -80.6% cumulative change since FY2023) , GAAP net income of -$10.5M, operating cash flow of -$4.2M, and free cash flow of -$4.2M (+48.9% YoY). On the balance sheet, ISPC closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.9M	-$10.5M	-$4.2M	-$4.2M	$9.5M	—
FY2024 (FY)	2024-12-31	$9.3M	-$12.5M	-$8.3M	-$8.3M	$9.4M	—
FY2023 (FY)	2023-12-31	$9.9M	-$11.1M	-$5.8M	-$5.8M	—	—

3. ISPC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ISPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ISPC compare to BIAF and ONMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ISPC?

Where is ISPC trading relative to its 50-day, 200-day, and 52-week technical levels?

ISPC last traded at $0.83 (+4.19% on volume of 543,348 shares), positioning the stock -31.40% below its 50-day simple moving average ($1.21) and -82.64% below its 200-day simple moving average ($4.78). Across its 52-week range of $0.75 to $32.96, ISPC sits at the 0.2% percentile with a 14-day RSI of 28.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.93).

ISPC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ISPC's next earnings date?

Based on SEC filing cadence, iSpecimen Inc. (ISPC)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ISPC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ISPC, spanning a range between $1 and $0.93.

Direct Sub-Reports: ISPC RQD Cockpit ISPC 12M Forecast ISPC Earnings & Move ISPC Dividends & DRIP ISPC Insiders & 13F ISPC Whale Options ISPC Profit Sankey ISPC News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ISPC — iSpecimen Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ISPC scores 30 out of 100 with a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 9 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on invested capital or free cash flow. The whale 13F flow pillar scores 3 of 20 and the insider conviction pillar scores 3 of 20, reflecting weak institutional and insider signal support. The macro regime fit pillar scores 7 of 20 (Beta 1.0; sector sensitivity). The forensic balance sheet pillar scores 8 of 20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor evaluating the stock today, the rating points to a business with negative returns, no free cash yield, weak ownership signals, and a forensic profile that the rating treats as elevated risk. Any upside case would need to rest on a change in those fundamentals, which the source data does not show.

Business

iSpecimen Inc. (ISPC) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Commercial Physical & Biological Resarch industry. The source data does not describe its specific products, customers, or revenue model beyond its reported revenue figures. Gross margin is reported at 11.2% per the market data section.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1.9M	$-9.0M	$-10.5M	N/A	$-4.2M	$6.9M	N/A
FY 2024	$9.3M	$-12.7M	$-12.5M	N/A	$-8.3M	$1.9M	N/A
FY 2023	$9.9M	$-11.2M	$-11.1M	N/A	$-5.8M	N/A	N/A

Per the SEC financials, revenue declined from $9.9M in FY 2023 and $9.3M in FY 2024 to $1.9M in FY 2025, while net income was negative in every reported period. Operating margin is reported at -60% and net margin at -60% per the market data section. ROIC is reported at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, both per the Roarable RQD rating, and Debt/Equity is 0.5 per the same source; the source does not provide the underlying debt figures.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the most prominent item is a report that a 1-for-10 to 1-for-100 reverse split goes to iSpecimen (ISPC) voters October 30, flagged as a market wire item. A Stock Titan item covering shipping of healthy donor blood the day it is collected is flagged green as a catalyst, though the source does not link it to a specific ISPC business event. Two items flagged red as risk watch report the stock falling -0.76% and watching $0.86 support as of 2026-10-20. A Benzinga item lists ISPC among 12 Health Care stocks moving in after-market trading. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Open Questions

What is the outcome of the reverse split vote scheduled for October 30, and what share-count change would result?
What products or services generate the reported revenue, and why did revenue decline from $9.9M in FY 2023 to $1.9M in FY 2025?
What are the debt, EPS, and forward earnings figures underlying the reported Debt/Equity and valuation gaps?
What is the cash runway given $6.9M cash against FY 2025 free cash flow of $-4.2M?
Do the reported news items link to any specific business event, or are they market-monitoring summaries?

ISPC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for iSpecimen Inc. (ISPC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ISPC Debate Forum (3) ↓

🟡 MARKET WIRE Stock Titan • 11h ago

A 1-for-10 to 1-for-100 reverse split goes to iSpecimen (ISPC) voters October 30.

Stock Titan report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 14h ago

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 17h ago

Healthy donor blood is generally shipped the day it's collected, aiming for next-day delivery.

Stock Titan report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.siam.in/ • 20h ago

iSpecimen (ISPC) Falls -0.76% — Watching $0.86 Support 2026-10-20 - Algorithmic Stock Picks

https://www.siam.in/ report covering iSpecimen Inc. (ISPC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 3d ago

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 4d ago

After-Hours Market Movers: Oct. 29, 2026 Gainers and Losers

Postmarket movers for Oct. 29, 2026: top after-hours gainers included SLGB, BURU and WKHS, while GCTK, LNAI and ATEC led the decliners.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 4d ago

iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent

Woburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully consented, prospective

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ISPC Bull vs. Bear Conversation Board — What's Your Call at $0.83?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ISPC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.70 (-11.4%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ISPC (E • RQD 30/100) a Buy at $0.79?

Welcome to the ISPC (iSpecimen Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.62 (-21.5%)

Spot @ $0.79

Pump the brakes on ISPC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ISPC, but look at what you are paying: current EV/EBITDA multiples with 11.2% gross margins. Unless iSpecimen Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.94 (+19.0%)

Spot @ $0.79

ISPC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ISPC, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $0.79 (52-wk range $0.75 - $32.96), any beat on forward guidance forces shorts and underweight funds to chase.